Researchers have introduced Foundayo™ (orforglipron), a new oral medication for weight loss that is now available in the U.S. This is the first GLP-1 pill that can be taken at any time of day without restrictions on food or water. In clinical trials, those taking the highest dose of Foundayo lost an average of 27 pounds, significantly more than those on a placebo, who lost just 2.2 pounds. This medication not only aids in weight loss but also helps reduce cardiovascular risk factors, such as waist circumference and cholesterol levels.

For adults looking to age well and maintain a healthy weight, Foundayo could be a game-changer. It is particularly beneficial for individuals with obesity or those who are overweight and have related health issues. The average weight loss of 27 pounds can lead to improved overall health, including better cardiovascular health, which is crucial as we age. This medication is intended to be used alongside a reduced-calorie diet and increased physical activity, making it a supportive tool in a holistic approach to weight management.

The evidence supporting Foundayo comes from the ATTAIN clinical trial program, which involved over 4,500 participants. These trials were rigorous and well-structured, providing strong evidence of the drug’s effectiveness for weight loss. However, it is important to note that while the results are promising, the medication is still relatively new, and ongoing studies are needed to fully understand its long-term safety and effectiveness.

If you’re considering Foundayo, it’s essential to consult with your healthcare provider to determine if it’s the right option for you, especially if you have existing health conditions or are taking other medications. Always approach new treatments with caution and ensure they fit into your overall health and wellness plan.

Source: investor.lilly.com